Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade and Caelyx in Ovarian Cancer
NCT00610792Phase 2Withdrawn
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jul 2006
- Primary completion
- Sep 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of bortezomib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Millennium Pharmaceuticals. Planned start Jul 2006; status: withdrawn.
02
Drugs
bortezomib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00610792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00610792.